Matharoo-Ball Balwir, Diop Mbayame, Kozlakidis Zisis
Director of Biobank, G42 Healthcare, Abu Dhabi, United Arab Emirates.
Université Cote d'Azur, Nice 06100, France.
Biosaf Health. 2022 Aug;4(4):280-282. doi: 10.1016/j.bsheal.2022.06.003. Epub 2022 Jul 9.
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the practice of infectious diseases biobanking, as well as existing challenges and opportunities. Thus, the future of infectious diseases biobanking in the post-pandemic era, shall not be an "entry-level version" of its counterpart in non-communicable diseases and large population cohorts, but incorporate the lessons learned. Biobanks constitute a critical research infrastructure supported by harmonized practices through the implementation of international standards, and perceived within the broader scope of healthcare's intersection with research. This perspective paper considers the barriers in biobanking and standardization of practices, as well as the emerging opportunities in the field.
2019年冠状病毒病（COVID-19）大流行凸显了传染病生物样本库的实践以及现存的挑战与机遇。因此，大流行后时代传染病生物样本库的未来不应是其在非传染性疾病和大型人群队列中的对应物的“入门版”，而应吸取经验教训。生物样本库是一个关键的研究基础设施，通过实施国际标准的统一做法提供支持，并在医疗保健与研究交叉的更广泛范围内被视为重要组成部分。本观点文章探讨了生物样本库和实践标准化方面的障碍以及该领域新出现的机遇。
